Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cetylpyridinium→

Cetylpyridinium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7773-52-6
Molecular formula
C21H38N+
Molecular weight
304.5 g/mol
Drug class
Quaternary ammonium antisepticoral cationic surfactant
Mechanism of action
Disrupts microbial cell membranes through adsorption to negatively charged membrane components, causing loss of membrane integrity and leakage of intracellular constituents.
Indications / reported uses
  • Adjunctive reduction of oral bacterial load, plaque and gingival inflammation in authorised mouth-rinse, lozenge and oral-care products; not a substitute for dental hygiene or treatment of invasive infection

Sources: US DailyMed — Cetylpyridinium chloride mouthwash/lozenge products · PubMed — Cetylpyridinium oral antiseptic evidence · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cetylpyridinium Environmental Risk Assessment (ERA) (the Cetylpyridinium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.